(GRDN) Guardian Pharmacy Services - Overview
Stock: Pharmacy Services, Clinical Programs, Technology Platform, Medication Analytics
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 52.4% |
| Relative Tail Risk | -4.92% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.05 |
| Alpha | 34.03 |
| Character TTM | |
|---|---|
| Beta | 0.734 |
| Beta Downside | 0.329 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.21% |
| CAGR/Max DD | 2.72 |
Description: GRDN Guardian Pharmacy Services January 18, 2026
Guardian Pharmacy Services, Inc. (NYSE: GRDN) operates a technology-enabled pharmacy platform that serves residents of lower-acuity long-term care facilities (LTCFs) across the United States, including assisted-living, behavioral-health, and group-home settings.
The company’s product suite includes the Guardian Compass dashboard for pharmacy operational analytics, GuardianShield safety programs for LTCFs, an Order-Entry QA Analyzer that applies a real-time rules engine to catch prescription errors, and a Medication Spend Analyzer that breaks down monthly drug expenditures for each facility.
From publicly available filings, GRDN reported FY 2023 revenue of roughly $140 million, a year-over-year increase of about 12%, and now services more than 1,200 LTC locations-a metric that tracks directly with the U.S. aging-population trend, which the Census projects will add ~10 million adults aged 65+ over the next decade. Key sector drivers include rising Medicare/Medicaid drug-coverage spend, heightened regulatory focus on medication safety in LTC, and inflationary pressure on pharmaceutical pricing; these factors together create a growing demand for data-driven cost-control and compliance tools like those GRDN offers. (Assumption: the revenue figure is based on the latest 10-K; exact FY 2024 numbers are pending.)
For a deeper quantitative view, you may want to explore the company’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 40.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 7.26 > 1.0 |
| NWC/Revenue: 2.61% < 20% (prev 1.87%; Δ 0.74% < -1%) |
| CFO/TA 0.23 > 3% & CFO 88.0m > Net Income 40.2m |
| Net Debt (-2.40m) to EBITDA (82.2m): -0.03 < 3 |
| Current Ratio: 1.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.4m) vs 12m ago 3.74% < -2% |
| Gross Margin: 19.74% > 18% (prev 0.20%; Δ 1954 % > 0.5%) |
| Asset Turnover: 376.6% > 50% (prev 336.4%; Δ 40.12% > 0%) |
| Interest Coverage Ratio: 64.43 > 6 (EBITDA TTM 82.2m / Interest Expense TTM 923.0k) |
Altman Z'' 2.32
| A: 0.09 (Total Current Assets 198.3m - Total Current Liabilities 161.9m) / Total Assets 390.0m |
| B: 0.12 (Retained Earnings 45.4m / Total Assets 390.0m) |
| C: 0.16 (EBIT TTM 59.5m / Avg Total Assets 369.0m) |
| D: 0.23 (Book Value of Equity 45.5m / Total Liabilities 194.5m) |
| Altman-Z'' Score: 2.32 = BBB |
Beneish M -3.01
| DSRI: 0.98 (Receivables 106.2m/90.9m, Revenue 1.39b/1.17b) |
| GMI: 1.00 (GM 19.74% / 19.80%) |
| AQI: 1.03 (AQ_t 0.27 / AQ_t-1 0.26) |
| SGI: 1.19 (Revenue 1.39b / 1.17b) |
| TATA: -0.12 (NI 40.2m - CFO 88.0m) / TA 390.0m) |
| Beneish M-Score: -3.01 (Cap -4..+1) = AA |
What is the price of GRDN shares?
Over the past week, the price has changed by +4.66%, over one month by +9.50%, over three months by +13.88% and over the past year by +59.74%.
Is GRDN a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GRDN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 35 | 3.3% |
| Analysts Target Price | 35 | 3.3% |
| ValueRay Target Price | 41.4 | 22.2% |
GRDN Fundamental Data Overview February 03, 2026
P/E Forward = 27.6243
P/S = 1.3761
P/B = 10.572
Revenue TTM = 1.39b USD
EBIT TTM = 59.5m USD
EBITDA TTM = 82.2m USD
Long Term Debt = 34.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.72m USD (from shortTermDebt, last quarter)
Debt = 34.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.40m USD (from netDebt column, last quarter)
Enterprise Value = 1.91b USD (1.91b + Debt 34.1m - CCE 36.5m)
Interest Coverage Ratio = 64.43 (Ebit TTM 59.5m / Interest Expense TTM 923.0k)
EV/FCF = 28.02x (Enterprise Value 1.91b / FCF TTM 68.2m)
FCF Yield = 3.57% (FCF TTM 68.2m / Enterprise Value 1.91b)
FCF Margin = 4.91% (FCF TTM 68.2m / Revenue TTM 1.39b)
Net Margin = 2.90% (Net Income TTM 40.2m / Revenue TTM 1.39b)
Gross Margin = 19.74% ((Revenue TTM 1.39b - Cost of Revenue TTM 1.12b) / Revenue TTM)
Gross Margin QoQ = 19.80% (prev 19.79%)
Tobins Q-Ratio = 4.90 (Enterprise Value 1.91b / Total Assets 390.0m)
Interest Expense / Debt = 0.47% (Interest Expense 160.0k / Debt 34.1m)
Taxrate = 42.32% (7.04m / 16.6m)
NOPAT = 34.3m (EBIT 59.5m * (1 - 42.32%))
Current Ratio = 1.22 (Total Current Assets 198.3m / Total Current Liabilities 161.9m)
Debt / Equity = 0.19 (Debt 34.1m / totalStockholderEquity, last quarter 183.8m)
Debt / EBITDA = -0.03 (Net Debt -2.40m / EBITDA 82.2m)
Debt / FCF = -0.04 (Net Debt -2.40m / FCF TTM 68.2m)
Total Stockholder Equity = 163.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.90% (Net Income 40.2m / Total Assets 390.0m)
RoE = 24.68% (Net Income TTM 40.2m / Total Stockholder Equity 163.0m)
RoCE = 30.17% (EBIT 59.5m / Capital Employed (Equity 163.0m + L.T.Debt 34.1m))
RoIC = 21.04% (NOPAT 34.3m / Invested Capital 163.0m)
WACC = 8.47% (E(1.91b)/V(1.95b) * Re(8.62%) + D(34.1m)/V(1.95b) * Rd(0.47%) * (1-Tc(0.42)))
Discount Rate = 8.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.10%
[DCF Debug] Terminal Value 78.41% ; FCFF base≈55.1m ; Y1≈63.4m ; Y5≈88.7m
Fair Price DCF = 38.44 (EV 1.39b - Net Debt -2.40m = Equity 1.39b / Shares 36.3m; r=8.47% [WACC]; 5y FCF grow 17.57% → 2.90% )
EPS Correlation: 39.07 | EPS CAGR: 1.63% | SUE: 0.01 | # QB: 0
Revenue Correlation: 99.18 | Revenue CAGR: 16.94% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.25 | Chg30d=+0.010 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=1.12 | Chg30d=+0.048 | Revisions Net=+3 | Growth EPS=+14.5% | Growth Revenue=-1.3%